- Infinty, like most of the stocks I cover, presented at Rodman and Renshaw - click here for complete webcast listings and links to my notes.
- See more details on company and pipeline on INFI research page.
- My quick notes (same slide deck as other recent presentstiaons)
- Longer than average description about biologic rationale for IPI-926 hedgehog inhibitor program [good overview if you're interested or new to the target]
- IPI-926 myelofibrosis trial will look at 12-15 patients first, look at response, maybe expand to 45 or so
- FDA and EMEA agreed on PFS endpoint for chondrosarcoma trial...no way to power study for survival with no prior trials
- IPI-504 HSP90 inhibitor: mTOR inhibitor preclinical model- decreases cellular antioxidants, proteotoxic stresses in ER. HSP90 induces ROS and same ER stress. Combo causes autophagy - cells die of lack of nutrients and "explode"
- Squamous cell histology of NSCLC- docetaxel is only 2nd line treatment option
- q&a session was not webcast
RSS Feed
